The safety and clinical efficacy of electro-thumbtack needle in the prevention of acute mountain sickness : a prospective, randomised, controlled study

注册号:

Registration number:

ITMCTR2023000065

最近更新日期:

Date of Last Refreshed on:

2023-12-04

注册时间:

Date of Registration:

2023-12-04

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

电揿针预防急性高原病安全性及临床疗效前瞻性随机对照研究

Public title:

The safety and clinical efficacy of electro-thumbtack needle in the prevention of acute mountain sickness : a prospective, randomised, controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

电揿针预防急性高原病安全性及临床疗效前瞻性随机对照研究

Scientific title:

The safety and clinical efficacy of electro-thumbtack needle in the prevention of acute mountain sickness: a prospective, randomised, controlled study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王馨

研究负责人:

刘佳

Applicant:

WANG Xin

Study leader:

Liu Jia

申请注册联系人电话:

Applicant telephone:

+86 135 5318 1286

研究负责人电话:

Study leader's telephone:

+86 188 1087 7011

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangxhope@163.com

研究负责人电子邮件:

Study leader's E-mail:

marie_liujia@sina.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国中医科学院中医临床基础医学研究所

研究负责人通讯地址:

北京市东城区东直门内南小街16号

Applicant address:

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

Study leader's address:

16 Dongzhimen South Street, Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100700

研究负责人邮政编码:

Study leader's postcode:

100700

申请人所在单位:

中国中医科学院中医临床基础医学研究所

Applicant's institution:

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

P23003/PJ02

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国中医科学院中医临床基础医学研究所医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2023/5/31 0:00:00

伦理委员会联系人:

顾浩

Contact Name of the ethic committee:

Gu Hao

伦理委员会联系地址:

北京市东城区东直门内南小街16号

Contact Address of the ethic committee:

16 Dongzhimen Nanxiao Street, Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6409 3248

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hebegu@126.com

研究实施负责(组长)单位:

中国中医科学院中医临床基础医学研究所

Primary sponsor:

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市东城区东直门内南小街16号

Primary sponsor's address:

16 Dongzhimen Nanxiao Street, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院中医临床基础医学研究所

具体地址:

北京市东城区东直门内南小街16号

Institution
hospital:

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

Address:

16 Dongzhimen Nanxiao Street, Dongcheng District, Beijing

经费或物资来源:

中国中医科学院第十五批定向委托项目

Source(s) of funding:

The 15th batch of directed commissioned projects of China Academy of Chinese Medical Sciences

研究疾病:

急性高原病

研究疾病代码:

Target disease:

Acute mountain sickness

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

通过安慰针随机对照临床试验,验证电揿针预防急性高原病的临床疗效,形成治疗方案。

Objectives of Study:

To verify the clinical effect of thumbtack needle treatment in the prevention of acute mountain sickness through a randomized controlled clinical trial of placebo thumbtack needle treatment and form a prevent scheme.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.受试者试验期间所处海拔高度≥3000m; 2.受试者到达高原时间不超过48小时; 3LLSS总分≥3分,并至少有1分的头痛; 4.年龄≥18岁,<65岁; 5.2月之内无高原生活和工作经历; 6.3个月之内未参加过其他临床试验; 7.自愿参加本研究,并签署知情同意。

Inclusion criteria

1. The subject is at an altitude of >= 3000m during the test; 2. The subject has not arrived on the plateau for more than 48 hours; 3. l LLSS score >= 3 and at least 1 headache; 4. Age >= 18 years and < 65 years; 5. No experience of living and working in a plateau within 2 months; 6. Not having participated in another clinical trial within 3 months; 7. Voluntary participation in this study and signed informed consent.

排除标准:

1.进驻高原前2周有头晕、慢性头痛、心脑血管疾病、慢性呼吸系统疾病、慢性消化系统疾病者; 2.合并其他严重疾病如恶性肿瘤及精神类疾病等影响本次研究评价的疾病; 3.电揿针禁忌者:如有心脏起搏器者; 4.上高原前2周内服用预防药物(包括乙酰唑胺、地塞米松、硝苯地平和磷酸二酯酶-3抑制剂)。

Exclusion criteria:

1. 2 weeks before entering the plateau with dizziness, chronic headache, cardiovascular and cerebrovascular diseases, chronic respiratory diseases, chronic digestive system diseases; 2.combined with other serious diseases such as malignant tumors and mental illnesses and other diseases that affect the evaluation of this study; 3.Those who are contraindicated to electro-snap needling: such as those who have cardiac pacemakers; 4. taking preventive drugs (including acetazolamide, dexamethasone, nifedipine and phosphodiesterase-3 inhibitors) within 2 weeks before plateauing.

研究实施时间:

Study execute time:

From 2023-04-01

To      2026-04-01

征募观察对象时间:

Recruiting time:

From 2023-08-01

To      2025-04-01

干预措施:

Interventions:

组别:

试验组

样本量:

128

Group:

experimental group

Sample size:

干预措施:

电揿针治疗

干预措施代码:

Intervention:

electrothumbtack needle treatment

Intervention code:

组别:

对照组

样本量:

128

Group:

Control group

Sample size:

干预措施:

安慰揿针

干预措施代码:

Intervention:

placebo thumbtack needle treatment

Intervention code:

样本总量 Total sample size : 256

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

西藏

市(区县):

Country:

China

Province:

Tibet

City:

单位(医院):

西藏大学

单位级别:

大学

Institution/hospital:

Tibetan University

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Bp

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

氧饱和度

指标类型:

次要指标

Outcome:

Oxygen saturation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AMS发生率

指标类型:

主要指标

Outcome:

Incidence of AMS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

微循环检测指标

指标类型:

次要指标

Outcome:

Microcirculation indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头痛严重程度

指标类型:

次要指标

Outcome:

VAS of headache

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

HR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AMS严重程度

指标类型:

次要指标

Outcome:

the severity of AMS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

格罗宁根睡眠质量调查量表

指标类型:

次要指标

Outcome:

GSQS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

斯坦福嗜睡程度量表

指标类型:

次要指标

Outcome:

SSS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

路易斯湖评分

指标类型:

次要指标

Outcome:

LLSS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AMS临床功能评分

指标类型:

次要指标

Outcome:

AMS clinical function score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 64
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用中国中医科学院临床评价中心中央随机系统(电话版和网络版)进行随机化操作,当受试者符合纳入排除标准进入研究时,由专门随机化的人员或临床研究者登陆中央随机系统进行随机化。按照2:1:1的比例将受试者随机分配到电揿针组、安慰揿针组和空白对照组。采用SAS统计分析软件的PROC PLAN 过程产生研究所需的随机方案,随机化过程中设定的各参数等相关内容均保存在盲底中。 本研究的随机化方案由中国中医科学院临床所临床评价中心产生,该人员不参与本项目的统计分析。 本研究的随机化方案以及产生该方案过程中设定的各个参数统称为盲底,由随机方案产生人员密封签名,并由中国中医科学院临床所不参与本项目的专门的课题组管理人员负责保管。中央随机系统设定了严格的人员权限,除最高级别的系统管理员外,其他人没有权限查看中央随机系统中的随机方案。

Randomization Procedure (please state who generates the random number sequence and by what method):

The central randomization system (telephone version and network version) of the clinical evaluation center of the Chinese Academy of traditional Chinese medicine was used for randomization. When the subjects met the inclusion and exclusion criteria and entered the study, special randomization personnel or clinical research.

盲法:

单盲(受试者盲)

Blinding:

Single blinding (for participant).

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过联系研究者公开。https://rwsreg.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Via contacting the researcher.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用中国中医科学院临床评价中心EDC系统进行数据采集和管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Adopt the EDC system of Clinical evaluation center, China academy of Chinese Medical Sciences.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above